Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug ...

Grace Therapeutics' GTx-104 met its Phase 3 trial endpoint, showing clinical benefits over oral nimodipine. US NDA submission ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRI ...

Grace Therapeutics (GRCE) announced that its Phase 3 STRIVE-ON safety trial met its primary endpoint and provides evidence of clinical benefit ...

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...

Grace Therapeutics has announced the initial closure of a financing round, securing almost $15m, to fund the pre-commercial ...

Grace Therapeutics is advancing its drug candidate, GTx-104, a novel injectable formulation of nimodipine for treating aneurysmal Subarachnoid Hemorrhage (aSAH), which aims to address significant ...

Grace Therapeutics Inc. (NASDAQ:GRCE), a $32.85 million market cap biotechnology company whose stock has gained over 37% in the past six months, has announced successful outcomes from its Phase 3 ...

NIMOTOP (nimodipine) is a calcium channel blocker indicated for patients with subarachnoid hemorrhage. It improves neurological outcome by relaxing cerebral smooth muscle vasculature and ...

PRINCETON, N.J. - Grace Therapeutics, Inc. (NASDAQ:GRCE), a biopharmaceutical company focused on developing treatments for ...

Nimodipine is initiated on admission in all patients with SAH for the prevention and treatment of vasospasm (Feigin, Rinkel, Algra, Vermeulen, & van Gijn, 1998; Rinkel et al., 2005). However ...